Real-World experience of tyrosine kinase inhibitors in patients with Desmoid-type-Fibromatosis

The use of Imatinib, Sorafenib and Pazopanib in the treatment of desmoid tumours has increased since the original trial was published a few years ago. The aim of this project is to add to the literature regarding real - world Canadian experience of tyrosine kinase inhibitors in patients with desmoids.

 
Corrigendum to “Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study” [Eur. J. Cancer, vol. 205 (2024) 114119] - ScienceDirect